Golden Helix is Launching VSPGx
The field of pharmacogenetics bridges genetics and pharmacology, with the aim of optimizing drug therapies for individual patients based on their unique genetic makeup. It has the potential to revolutionize healthcare by improving drug efficacy, reducing adverse reactions, and advancing the concept of personalized medicine moving away from a one size fits all approach.
"VSPGx has been demanded by our customers world-wide. Golden Helix partnered with the NIH, who awarded us with a phase 1 SBIR (Award 1R43HG013456 – 01) to develop a first product addressing a vast need for this type of solution in the marketplace," says Dr.
The Golden Helix ACMG User Meeting is a pre-conference meeting. Golden Helix will share the latest advancements and updates, including the launch of VSPGx. Other talks are covering topics such as whole genome analysis using long-read data and updates on Golden Helix CancerKB. Please visit https://bit.ly/3uFpyuP to register and learn more about the meeting.
About Golden Helix
Golden Helix has been delivering industry-leading bioinformatics solutions for over a quarter century with thousands of users worldwide. Golden Helix enables hospitals, testing labs, research institutions, and country-wide genome initiatives to conduct a wide spectrum of clinical tests and facilitate genomic research. With its solutions, Golden Helix users can harness the full potential of genomics to identify the cause of disease, gain diagnostic insights, and improve the efficacy and safety of drug treatments advancing the quest for personalized medicine. Since 2017, the company has received a total of
Director of Marketing
Golden Helix, Inc
(406) 551-4901
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/golden-helix-is-launching-vspgx-302069995.html
SOURCE Golden Helix Inc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI is redesigning work: Adecco Group whitepaper reveals the need for hybrid workforce orchestration
- Half-year results 2026: execution driving RIG
- Cosmo Reports Double-Digit Recurring Revenue Growth in H1 2026, Advances Clascoterone 5% Topical Solution Toward Regulatory Submission, and Confirms Full-Year Guidance
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share